期刊文献+

脊痹丸对强直性脊柱炎骨代谢的影响

Effect of Jibi pill on bone metabolism in ankylosing spondylitis
下载PDF
导出
摘要 目的:通过检测强直性脊柱炎患者骨组织中的碱性磷酸酶、抗酒石酸酸性磷酸酶的水平,探讨脊痹丸对强直性脊柱炎骨代谢的影响。方法:选取符合纳入标准的30例男性患者,予美洛昔康胶囊口服,脊痹丸口服。疗程为3个月。于治疗前后,分别检测患者血清骨碱性磷酸酶(BALP)和抗酒石酸酸性磷酸酶异构体(TRACP-5b)水平,采用酶联免疫吸附试验法(ELISA)检测。结果:TRACP-5b水平在治疗后降低,差异有统计学意义,而治疗前后的BALP水平差异无统计学意义。结论:TRACP-5b与骨吸收水平呈正相关,推测脊痹丸可以通过降低TRACP-5b水平抑制骨吸收,而发挥抗骨质疏松的作用。 Objective:To verify the serum levels of bone metabolic indices in patients with ankylosing spondylitis before and after Jibi pill treatment and detect effect of Jibi pill on bone metabolism in ankylosing spondylitis.Methods:30cases of male patients were diagnosed ankylosing spondylitis inpatients or outpatients,met the inclusion criteria and without any of the exclusion criteria.All cases were received treatment with meloxicam capsules and Jibi pill,and they were treated for 3months.Respectively analysing the serum levels of bone metabolic indices before and after treatment.The tartrate-resistant acid phosphatase isomer(TRACP-5b)serum levels and bone-specific alkaline phosphatase(BALP)serum levels were detected by enzymelinked immunosorbent assay(ELISA)method.Results:Compared before and after treatment,the serum levels of TRACP-5b were decreased(P〈0.05).The serum levels of BALP had no significant difference(P〉0.05).Conclusion:The reduction of TRACP-5bafter treatment suggests that Jibi pill can inhibit bone resorption and this relevants to anti osteoporosis.
作者 杨金连 郑宝林 Yang Jinlian Zheng Baolin(Department of Rheumatology, Affiliated Foshan Hospital, GuangZhou University of Traditional Chinese Medicine (Foshan 528000)
出处 《陕西中医》 2017年第5期592-593,共2页 Shaanxi Journal of Traditional Chinese Medicine
关键词 脊柱炎 强直性/中西医结合疗法 @脊痹丸 碱性磷酸酶 Spondylitis,ankylosing/integrated Chinese traditional and western medicine therapy @Jibi pill Alkaline phosphatase
  • 相关文献

参考文献7

二级参考文献81

  • 1刘红,廖二元,伍贤平,张红,罗湘杭,谢辉,曹行之,刘石平.正常女性与年龄相关的骨转换生化指标和骨密度的关系[J].中华内科杂志,2004,43(11):805-809. 被引量:27
  • 2VAN DER LINDEN S, VALKENBURG H A, CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteria [J]. Arthritis Rheum, 1984, 27 (4): 361-368.
  • 3DOUGADOS M, VAN DER LINDEN S, JUHLIN R, et al. The European Spondylarthropathy Study Group prelim- inary criteria for the classification of spondylarthropathy [J]. Arthritis Rheum, 1991, 34 (10): 1218-1227.
  • 4RUDWALEIT M, VAN DER HEIJDE D, LANDEWE, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part Ⅱ) : validation and final selection [J]. Ann Rheum Dis, 2009, 68 (6): 777-783.
  • 5ZOCHLING J, VAN DER HEIJDE D, DOUGADOS M, et al. Current evidence for the management of ankylosing spondylitis, a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis[J]. Ann Rheum Dis, 2006, 65(4) : 423-432.
  • 6邓兆智 熊曼琪.内分泌科专病与风湿病中医临床诊治[M].北京:人民卫生出版社,2000.108.
  • 7蒋明 朱立平 林孝文.风湿病学[M].北京:北京科学技术出版社,1996.798,845.
  • 8Garrett S,Jenkinson T,Whitelock H,et al.A new approach to defining disease status in AS:the Bath Ankylosing Spondylitis Disease Activity Index(BASDAI).J Rheumatol,1994,21(12):2286~2291
  • 9Calin A,Garrett S,Whitelock H,et al.A new approach todefining functional ability in ankylosing spondylitis:the development of the Bath Ankylosing Spondylitis Functional Index(BASFI).J Rheumatol,1994,21(12):2281~2285
  • 10Dougados M,Linden S,Leirisalo-Repo M.et al.Sulfasalazine in the treatment of spondylarthropathy.Arandomized,mulficenter,double-blind,placebo-controlled study.Arthritis Rheum,1995,38(5):618~627

共引文献192

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部